Acute Respiratory Distress Syndrome
539
76
84
252
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
51 trials with published results (9%)
Research Maturity
252 completed trials (47% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.2%
44 terminated out of 539 trials
85.1%
-1.4% vs benchmark
9%
51 trials in Phase 3/4
20%
51 of 252 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 252 completed trials
Clinical Trials (539)
Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)
A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Treatment of ARDS With Sivelestat Sodium
The Burden of Acute Respiratory Failure in Chinese ICUs: a National Cohort Study
Prediction of Outcomes With a Miniaturized Transesophageal Echocardiography Probe in Patients With Acute Respiratory Distress Syndrome
Long Term (1 Year) Respiratory Sequelae in Children Surviving an Acute Respiratory Distress Syndrome
Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)
SEvoflurane for Sedation in ARds
Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome
Prediction of Inspiratory Effort Response to High PEEP in Patients Recovering From ARDS
"Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress syndrOme"
Corticosteroids in Hyperinflammatory Phenotype of Critical Illness
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).